Recent advances in closed-loop insulin delivery

Drucker, 2021, Transforming type 1 diabetes: the next wave of innovation, Diabetologia, 64, 1059, 10.1007/s00125-021-05396-5 Pickup, 2019, Is insulin pump therapy effective in type 1 diabetes?, Diabet Med, 36, 269, 10.1111/dme.13793 Danne, 2017, International consensus on use of continuous glucose monitoring, Diabetes Care, 40, 1631, 10.2337/dc17-1600 Thabit, 2020, Use of factory-calibrated real-time continuous glucose monitoring improves time in target and HbA1c in a multiethnic cohort of adolescents and young adults with type 1 diabetes: the MILLENNIALS study, Diabetes Care, 43, 2537, 10.2337/dc20-0736 Tauschmann, 2020, Reduction in diabetic ketoacidosis and severe hypoglycemia in pediatric type 1 diabetes during the first year of continuous glucose monitoring: a multicenter analysis of 3,553 subjects from the DPV Registry, Diabetes Care, 43, e40, 10.2337/dc19-1358 Dovc, 2019, Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery, Diabetes Care, 42, 1344, 10.2337/dc18-2625 Foster, 2019, State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018, Diabetes Technol Ther, 21, 66, 10.1089/dia.2018.0384 Boughton, 2019, Is an artificial pancreas (closed-loop system) for type 1 diabetes effective?, Diabet. Med., 36, 279, 10.1111/dme.13816 Forlenza, 2018, Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial, Diabetes Care, 41, 2155, 10.2337/dc18-0771 Bergenstal, 2013, Threshold-based insulin-pump interruption for reduction of hypoglycemia, N Engl J Med, 369, 224, 10.1056/NEJMoa1303576 Battelino, 2017, Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial, Diabetes Care, 40, 764, 10.2337/dc16-2584 Boughton, 2021, New closed-loop insulin systems, Diabetologia, 64, 1007, 10.1007/s00125-021-05391-w Galderisi, 2020, Effect of Afrezza on glucose dynamics during HCL treatment, Diabetes Care, 43, 2146, 10.2337/dc20-0091 Bekiari, 2018, Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis, BMJ, 361 Lee, 2020, Glucose and counterregulatory responses to exercise in adults with type 1 diabetes and impaired awareness of hypoglycemia using closed-loop insulin delivery: a randomized crossover study, Diabetes Care, 43, 480, 10.2337/dc19-1433 Tagougui, 2018, The benefits and limits of technological advances in glucose management around physical activity in patients type 1 diabetes, Front Endocrinol (Lausanne), 9, 818, 10.3389/fendo.2018.00818 Burckhardt, 2021, Impact of hybrid closed loop therapy on hypoglycemia awareness in individuals with type 1 diabetes and impaired hypoglycemia awareness, Diabetes Technol Ther, 23, 482, 10.1089/dia.2020.0593 Sherr, 2018, Closing the loop on managing youth with type 1 diabetes: children are not just small adults, Diabetes Care, 41, 1572, 10.2337/dci18-0003 Tauschmann, 2019, Home use of day-and-night hybrid closed-loop insulin delivery in very young children: a multi-center, 3-week, randomized trial, Diabetes Care, 42, 594, 10.2337/dc18-1881 Fuchs, 2021, 57th EASD Annual Meeting of the European Association for the Study of Diabetes: OP 41 building the evidence base for new devices; 233 Cambridge hybrid closed-loop in very young children with type 1 diabetes: a multi-national 4-month randomised trial, Diabetologia, 64, S122 Fuchs, 2021, Benefits and challenges of current closed-loop technologies in children and young people with type 1 diabetes, Front Pediatr, 9, 10.3389/fped.2021.679484 Ruan, 2015, Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial, Diabetologia, 58, 687, 10.1007/s00125-014-3483-6 Pratley, 2020, Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial, JAMA, 323, 2397, 10.1001/jama.2020.6928 McAuley, 2021, 212-OR: closed-loop increases time-in-range in older adults with type 1 diabetes compared with sensor-augmented pump therapy: a randomized crossover trial, Diabetes, 70, 10.2337/db21-212-OR Macintosh, 2006, Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study, BMJ, 333, 177, 10.1136/bmj.38856.692986.AE Murphy, 2017, Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study, Diabetologia, 60, 1668, 10.1007/s00125-017-4314-3 Stewart, 2018, Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: a randomized controlled crossover trial, Diabetes Care, 41, 1391, 10.2337/dc17-2534 Peters, 2018, Dual-hormone artificial pancreas: benefits and limitations compared with single-hormone systems, Diabet Med, 35, 450, 10.1111/dme.13581 El-Khatib, 2017, Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial, The Lancet, 389, 369, 10.1016/S0140-6736(16)32567-3 Castellanos, 2021, Performance of the insulin-only iLet Bionic Pancreas and the bihormonal iLet using Dasiglucagon in adults with type 1 diabetes in a home-use setting, Diabetes Care, 44, e118, 10.2337/dc20-1086 Wilson, 2020, Dual-hormone closed-loop system using a liquid stable glucagon formulation versus insulin-only closed-loop system compared with a predictive low glucose suspend system: an open-label, outpatient, single-center, crossover, randomized controlled trial, Diabetes Care, 43, 2721, 10.2337/dc19-2267 Haidar, 2020, A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial, Diabetes Care, 43, 597, 10.2337/dc19-1922 Andersen, 2021, ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes, Diabetes Obes. Metab., 23, 961, 10.1111/dom.14302 Majdpour, 2021, Fully automated artificial pancreas for adults with type 1 diabetes using multiple hormones: exploratory experiments, Can J Diabetes, 10.1016/j.jcjd.2021.02.002 Dimitrios, 2020, Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis, Curr Diabetes Rev, 16, 313 Johansen, 2020, Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, 8, 313, 10.1016/S2213-8587(20)30030-9 Srinivasan, 2021, Adjunctive therapies to optimize closed-loop glucose control, J Diabetes Sci Technol, 15, 1243, 10.1177/19322968211032701 Dandona, 2018, Efficacy and safety of Dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study, Diabetes Care, 41, 2552, 10.2337/dc18-1087 McAuley, 2020, Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized, controlled trial, Diabetes Care, 43, 3024, 10.2337/dc20-1447 Forlenza, 2019, Safety evaluation of the MiniMed 670G System in children 7-13 years of age with type 1 diabetes, Diabetes Technol Ther, 21, 11, 10.1089/dia.2018.0264 Abraham, 2021, Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial, JAMA Pediatr, 10.1001/jamapediatrics.2021.3965 Bergenstal, 2021, A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial, Lancet, 397, 208, 10.1016/S0140-6736(20)32514-9 Lal, 2019, One year clinical experience of the first commercial hybrid closed-loop system, Diabetes Care, 42, 2190, 10.2337/dc19-0855 Collyns, 2021, Improved glycemic outcomes with Medtronic MiniMed Advanced Hybrid Closed-Loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes, Diabetes Care, 44, 969, 10.2337/dc20-2250 Brown, 2018, First look at control-IQ: a new-generation automated insulin delivery system, Diabetes Care, 41, 2634, 10.2337/dc18-1249 Anderson, 2016, Multinational home use of closed-loop control is safe and effective, Diabetes Care, 39, 1143, 10.2337/dc15-2468 Brown, 2019, Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes, N Engl J Med, 381, 1707, 10.1056/NEJMoa1907863 Breton, 2020, A randomized trial of closed-loop control in children with type 1 diabetes, N Engl J Med, 383, 836, 10.1056/NEJMoa2004736 Ekhlaspour, 2020, Safety and performance of the Tandem t:slim X2 with Control-IQ automated insulin delivery system in toddlers and preschoolers, Diabetes Technol Ther, 23, 384, 10.1089/dia.2020.0507 Schierloh, 2019, Lower plasma insulin levels during overnight closed-loop in school children with type 1 diabetes: potential advantage? A randomized cross-over trial, PLoS One, 14, 10.1371/journal.pone.0212013 Hovorka, 2011, Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies, BMJ, 342, 10.1136/bmj.d1855 Bally, 2017, Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study, Lancet Diabetes Endocrinol, 5, 261, 10.1016/S2213-8587(17)30001-3 Tauschmann, 2016, Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized crossover trial, Diabetes Care, 39, 2019, 10.2337/dc16-1094 Tauschmann, 2018, Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial, Lancet, 392, 1321, 10.1016/S0140-6736(18)31947-0 Fuchs, 2021, 214-OR: Cambridge hybrid closed-loop in children and adolescents with T1D: a multicentre six-month randomised trial, Diabetes, 70, 10.2337/db21-214-OR Boughton, 2021, Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study, Diabetes Obes Metab, 23, 1389, 10.1111/dom.14355 Benhamou, 2019, Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial, Lancet Digit Health, 1, e17, 10.1016/S2589-7500(19)30003-2 Amadou, 2021, Diabeloop DBLG1 closed-loop system enables patients with type 1 diabetes to significantly improve their glycemic control in real-life situations without serious adverse events: 6-month follow-up, Diabetes Care, 44, 844, 10.2337/dc20-1809 Kariyawasam, 2021, 98-LB: Diabeloop DBL4K hybrid closed-loop system improves time-in-range without increasing time-in-hypoglycemia in children aged 6–12 years, Diabetes, 70, 10.2337/db21-98-LB Brown, 2021, Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes, Diabetes Care, 44, 1630, 10.2337/dc21-0172 Sherr, 2021, 70-OR: evaluation of the Omnipod 5 Automated Insulin Delivery System in very young children with type 1 diabetes (T1D), Diabetes, 70, 10.2337/db21-70-OR Lum, 2021, A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system, Diabetes Technol Ther, 23, 367, 10.1089/dia.2020.0535 Jennings, 2019, Do-it-yourself artificial pancreas systems: a review of the emerging evidence and insights for healthcare professionals, J Diabetes Sci Technol, 14, 868, 10.1177/1932296819894296 Burnside, 2020, J Diabetes Metab Disord, 1 Rankin, 2021, Adolescents’ and their parents’ experiences of using a closed-loop system to manage type 1 diabetes in everyday life: qualitative study, Chronic Illn Lawton, 2019, Participants’ experiences of, and views about, daytime use of a day-and-night hybrid closed-loop system in real life settings: longitudinal qualitative study, Diabetes Technol Ther, 21, 119, 10.1089/dia.2018.0306 Farrington, 2018, Women’s experiences of day-and-night closed-loop insulin delivery during type 1 diabetes pregnancy, J Diabetes Sci Technol, 12, 1125, 10.1177/1932296818800065 Barnard, 2017, Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy, J Diabetes Sci Technol, 11, 1080, 10.1177/1932296817702656 Musolino, 2019, Reduced burden of diabetes and improved quality of life: experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes, Pediatr Diabetes, 20, 794 Berget, 2020, Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system, Pediatr Diabetes, 21, 310, 10.1111/pedi.12962 Breton, 2021, One year real-world use of the Control-IQ advanced hybrid closed-loop technology, Diabetes Technol Ther, 23, 601, 10.1089/dia.2021.0097 Da Silva, 2021, Real-world performance of the MiniMed 780G System: first report of outcomes from 4’120 users, Diabetes Technol Ther Leelarathna, 2020, Hybrid closed-loop therapy: where are we in 2021?, Diabetes Obes Metab, 1-6 Weinzimer, 2008, Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas, Diabetes Care, 31, 934, 10.2337/dc07-1967 Dovc, 2020, Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: a double-blind randomized crossover trial, Diabetes Care, 43, 29, 10.2337/dc19-0895 Cameron, 2017, Closed-loop control without meal announcement in type 1 diabetes, Diabetes Technol Ther, 19, 527, 10.1089/dia.2017.0078 Messer, 2019, A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm, Diabetes Technol Ther, 21, 462, 10.1089/dia.2019.0105 Kimbell, 2020, What training, support, and resourcing do health professionals need to support people using a closed-loop system? A qualitative interview study with health professionals involved in the Closed Loop from Onset in type 1 Diabetes (CLOuD) trial, Diabetes Technol Ther, 22, 10.1089/dia.2019.0466 Lal, 2019, Realizing a closed-loop (artificial pancreas) system for the treatment of type 1 diabetes, Endocr Rev, 40, 1521, 10.1210/er.2018-00174 Wang, 2014, Intensive insulin therapy for critically ill subjects based on direct data-driven model predictive control, J Process Control, 24, 493, 10.1016/j.jprocont.2013.12.012 Mauseth, 2013, Use of a “fuzzy logic” controller in a closed-loop artificial pancreas, Diabetes Technol Ther, 15, 628, 10.1089/dia.2013.0036